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identify subgroups of patients who are more likely to beneﬁt from an
adapted conditioning regimen or from early post transplant therapeutic
strategies such as preemptive/prophylactic donor lymphocytes infusion
and/or hypo-methylating agents.
This analysis is hampered by the limited number of patients ana-
lyzed and by the usual limitations related to its retrospective nature.
However these data, considering very high-risk features of disease
in more than 50% of patients and elevated median comorbidity
index are encouraging and deserve further studies. A larger prospec-
tive trial of haploidentical transplant in higher risk MDS patients
ﬁtting with the procedure and lacking an HLA identical donor is
warranted.
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Adrenal insuﬃciency: An
emerging challenge in
thalassemia?
To the Editor:
Due to dramatic improvements in disease management, thalassemia
major patients are now surviving into their ﬁfties and sixties, and face
new unexpected medical issues that may require urgent recognition
and treatment.
Iron overload, due to blood transfusion and to increased iron
absorption from ineﬀective erythropoiesis, still remains the principal
cause of morbidity in patients with transfusion-dependent thalassemia
(TDT).1 Endocrine functions are markedly aﬀected by iron overload,
with the most frequent deﬁciency being hypogonadotropic
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hypogonadism, followed by diabetes mellitus, hypothyroidism, and
hypoparathyroidism. The hypothalamic–pituitary–adrenal (HPA) axis is
generally considered to be an infrequent target of chronic iron toxic-
ity.2 Since adrenal insuﬃciency may have dramatic consequences in
conditions of stress such as sepsis, acute diseases, trauma, and surgery,
an early diagnosis is crucial.
We report here three cases of adrenal insuﬃciency diagnosed in
an acute setting, in TDT patients. Interestingly, none of them had previ-
ously shown symptoms and clinical signs of adrenal insuﬃciency and
all had previously normal basal serum cortisol and ACTH values.
Case 1: A 52-year-old male patient was admitted to the Intensive
Care Unit in November 2015 for septic shock due to bacterial pneumo-
nia, complicated by atrial ﬁbrillation and heart failure. He was on oral
iron chelation therapy with deferasirox (DFX), and the last T2* cardio-
vascular magnetic resonance (CMR) didn’t show liver or cardiac iron
overload (Table 1). He had hypogonadotropic hypogonadism, type 2
diabetes, and hypoparathyroidism, all treated with good compliance
and results. With the septic shock being unresponsive to intravenous
norepinephrine, an adrenal crisis was suspected, and subsequently con-
ﬁrmed by the prompt reversal of hypotension following IV administra-
tion of hydrocortisone. The diagnosis was later conﬁrmed by low
serum cortisol and ACTH values.
Case 2: A 44-year-old male patient was admitted to the Intensive
Care Unit in February 2015 for severe sepsis associated with hypona-
tremia, hypoglycemia, and altered mental state. He was on chelation
therapy with DFX and had no liver or heart iron overload at the last
T2* CMR (Table 1). The only known endocrine deﬁciency was hypogo-
nadotropic hypogonadism. A severe hypoglycemia unresponsive to
continuous IV glucose administration led to the clinical suspicion of
adrenal insuﬃciency; after IV administration of hydrocortisone, blood
glucose levels normalized. Once clinical conditions stabilized, an ACTH
stimulation test conﬁrmed the diagnosis of adrenal insuﬃciency.
Case 3: In a 40-year-old male patient, a giant myelolipoma originat-
ing in the right adrenal gland was surgically removed.3 He was on iron
chelation with DFX with no liver or heart iron overload detected at the
last T2* CMR (Table 1). The only known endocrine deﬁciency was
hypogonadotropic hypogonadism, on testosterone replacement. Basal
adrenal function was normal; however an ACTH stimulation test prior
to surgery was positive for adrenal insuﬃciency. Replacement with cor-
tisone acetate was immediately started, and surgery was uneventful.
Published data about adrenal insuﬃciency in adult thalassemic
patients are scarce, since most studies include patients in their early
decades of life.4,5 The reported prevalence of this complication is
extremely variable, depending on iron overload severity, available treat-
ments, and diagnostic criteria.
Iron toxicity can aﬀect the HPA axis at diﬀerent levels. The pres-
ence of high ACTH serum concentrations is consistent with direct dam-
age to the adrenal glands, which can be conﬁrmed by magnetic
resonance imaging (MRI).6 Lower than normal ACTH levels suggest
secondary (central) adrenal insuﬃciency due to pituitary iron deposi-
tion, although combined central and peripheral impairments cannot be
ruled out.
Adrenal insuﬃciency develops gradually, and symptoms, such as
fatigue, may be aspeciﬁc and overlapping with those of chronic anemia.
The main risk of undetected disease is that it may present with a life-
threatening acute crisis. The hypothesis that subclinical adrenal impair-
ment may be more common than expected in TDT patients, and some-
times revealed by conditions of stress, has been formulated by Scacchi
et al.7 In 2010, they described a subnormal response to low-dose tetra-
cosactide test in 32.1% of adult thalassemia patients with normal basal
cortisol and ACTH values. At our Rare Disease Center, the annual
endocrinological assessment of TDT patients always included basal
adrenal function evaluation (ACTH and cortisol basal levels). Since a
normal basal function cannot rule out a reduced functional reserve, we
are now reconsidering new criteria for performing or repeating the
stimulation test. Recently, De Sanctis et al., in a survey on hematolo-
gists and endocrinologists, showed poor knowledge in the diagnostic
criteria for secondary adrenal insuﬃciency among hematologists, while
higher awareness and knowledge of proper diagnostic criteria were
TABLE 1 Clinical parameters of described patients
Patient 1 Patient 2 Patient 3
Age (years) at diagnosis of adrenal insuﬃciency 52 44 40
Ferritin (ng/mL) 450-850 200-400 300-400
Cardiac T2* (msec) 32 43 73
Liver T2* (msec) 8 17 21
Chelation therapy Deferasirox Deferasirox Deferasirox
Dose 20 mg/kg/day 15 mg/kg/day 15 mg/kg/day
Basal serum ACTH (pg/mL) 26.5 75 21.9
Basal serum cortisol (mcg/dL) 6.0 9.3 6.6
ACTH test:
Basal cortisol (nv 6.2-19.4 mcg/dL) 6.0 7.2 5.7
Cortisol peak (nv>18 mcg/dL) 10.6 13.6 13.2
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found in centers with a dedicated endocrinologist and an established
multidisciplinary approach.8 Further studies on larger thalassemic popu-
lations, including non-transfusion dependent thalassemia patients, are
needed to establish criteria leading to the decision of performing
dynamic tests of adrenal functions, as well as the appropriate use of
these tests to inform clinical decisions.
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A comment on improving
transcranial Doppler
ultrasonography screening in
children with sickle cell
anemia
To the Editor:
Regular screening with transcranial Doppler ultrasonography (TCD)
is a crucial component of primary stroke prevention for children with
sickle cell anemia (SCA).1 Despite being the standard of care for nearly
two decades, TCD screening rates remain low.2 In a paper recently
published in the American Journal of Hematology, Adams et al. reported
TCD re-screening rates for 1896 eligible children receiving care at 19
of the 26 original sites that participated in the pivotal STOP and/or
STOP II trials.2 Only 57% of eligible patients had any follow-up TCD
screening performed over a ﬁve year period, with signiﬁcant variation
by site (18-91%). The authors expressed concern that TCD screening
protocols were not fully implemented even in these experienced
centers. Other sickle cell centers have reported similar experiences
with TCD screening among children with SCA, with rates ranging from
22% to 45%.3,4
For the past six years, we have utilized systems-based processes
to achieve high TCD screening rates. We oﬀer our results to demon-
strate the eﬃcacy of these methods, as our screening rates among
eligible children with SCA have been 70% since 2011. Approximately
200 children with sickle cell disease receive care in our pediatric hema-
tology practice, which is based in an urban safety net academic institu-
tion. As an HRSA Sickle Cell Disease Newborn Screening grantee from
2011-2015, we implemented an electronic health record (EHR)-based
patient registry and used a part-time patient navigator to work with
providers and families to achieve consistently high TCD screening
rates.5 Even though our grant funding ended in 2015, we have main-
tained high TCD screening rates without additional staﬀ, surpassing
most screening rates reported to date (Table 1).
To achieve and maintain these results, we have made two signiﬁ-
cant changes to our approach to patient care. First, we have incorpo-
rated our EHR-based patient registry reporting functions into regular
clinic workﬂow, which has enabled us to provide better care to our
entire patient population. Population-based lists are generated weekly
for all children seen in our clinic and reviewed at our multidisciplinary
hematology team meetings that include both clinical and administrative
staﬀ. All patients who are overdue for TCD are identiﬁed and con-
tacted by administrative staﬀ to schedule necessary screenings. In
addition, an “opportunity report” is generated prior to each clinic
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